Viral Disease Diagnosis Market

Viral Disease Diagnosis Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 255

To learn more about this report, request a free sample copy

Viral Disease Diagnosis Market Overview

The report is titled as ‘Viral Disease Diagnosis Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the Viral Disease Diagnosis market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Viral Disease Diagnosis market is expected to grow with significant rate in the near future.

The viral disease diagnosis market is estimated to reach at a value of US$ 18,560.5 Mn by the end of 2022 and expected to reach at a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2%.

Viral Disease Diagnosis Introduction

Viruses or infectious substances can be perceived as extremely tiny or minute organisms that are composed of genetic material and have the potential to induce infection into the human body. These viruses trespass, occupy and attach themselves to a host cell, thus terminating or changing the function of that cell. As a result, such activity causes an infection in the human body. Notably, there are a number of ways by which viruses can be transported, for instance, any kind of contact with an already infected person, or unsafe intercourse. The inadequate personal hygiene is also likely to increase the chances of virus infection.

Viral disease diagnosis is an extremely essential step to mitigate the odds of epidemics and in order to provide treatment at the right time. The heavy load of viral diseases among the population persists to be a general concern across communities all around the world, majorly after the Covid-19 global pandemic. Having said that, the sudden outbreak of Covid-19 global crisis positively influenced the global viral disease diagnosis market. In order to support that, in accordance with the World Health Organization, as of 24th February 2022, there were roughly around 428,511,601 confirmed cases of COVID-19 infection across the world. Though diagnostics for SARS-CoV-2 screening are being developed in a constant manner in order to cater to the needs of markets with exclusive regulatory constraints

Advances in clinical research and molecular diagnostic technology is expected to drive the viral molecular diagnosis market

The primary challenge for virus detection changes in the viral genome. As a result, diagnosis becomes more difficult. As a result, new microarray techniques and rapid tests are emerging. Increased research and development for virus detection are expected to drive global virological diagnosis. According to the WHO, 1.5 million new infections occur worldwide each year. This increase in infection rates will directly benefit the viral diagnostic market.

Furthermore, with the reduction of detection time and the selection of effective treatment methods, the development of rapid and accurate detection and testing has aided market growth. Furthermore, the increased awareness of viral infections and the availability of diagnostic tests for viral infectious diseases are expected to drive the viral molecular diagnostics market.

Key Takeaways from the Market Study

  • The viral disease diagnosis market is estimated to reach at a value of US$ 18,560.5 Mn by the end of 2022 and expected to reach at a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2%.
  • The assays, kits & reagent product type segment in viral disease diagnosis market is expected to create an incremental opportunity of US$ 4,821.7 Mn during the forecast period
  • In 2022, the Rapid Antigen Detection Tests (RADTs) technique segment accounted for the largest market share and expected to grow at 6.5% CAGR during the forecast period.
  • The U.S. viral disease diagnosis market is expected to create an incremental opportunity of US$ 3,571.7 Mn during the forecast period
  • In 2020, the North America region accounted for the largest market share and expected to grow at a significant CAGR during the forecast period
  • Viral disease diagnosis market is expected to increase 1.6X times during the forecast period of 2022 to 2030

Viral Disease Diagnosis Market Segmentation

The global viral disease diagnosis market is segmented on the basis of technique, product, virus type, end use, and region

By Technique

Polymerase Chain Reaction (PCR)

Rapid Antigen Detection Tests (RADTs)

Multiplex PCR

Real-Time PCR

Reverse Transcription-PCR (RT-PCR)

Nested-PCR

By Product

Assays, Kits, & Reagents

Instruments

Services & Software

By Virus Type

HIV infection

SARS-CoV

Respiratory syncytial virus (RSV)

Influenza viruses.

hepatitis C virus

hepatitis B virus

hepatitis A virus

Influenza A and Influenza B viruses

By End-Use

Homecare

Diagnostic Centres

Nursing homes

Hospitals

Clinics

Laboratories

By Region

North America

Latin America

Asia Pacific

Europe

Middle East

Africa

Viral Disease Diagnosis Market Key Players

Some of the key participating players in global Viral Disease Diagnosis market are:

Thermo Fisher Scientific

Adaltis S.r.l

R-Biopharm AG

Siemens Healthcare Private Limited

Toronto Bioscience

Merck KGaA

Abbott Laboratories

BioMérieux SA

Cepheid

Epitope Diagnostics Inc.

F. Hoffmann-La Roche Ltd

Becton Dickinson and Company

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

Global Healthcare Industry Outlook

Medical Treatment Growth Outlook

Requirement for Viral testing and treatment

Concerns for growing viral infections

Top Companies Historical Growth Rate

Pricing Impact

Impact of Regulations

Growth in investment in healthcare sector

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.


To learn more about this report, request a free sample copy


Select License Type

Frequently Asked Questions

The viral disease diagnosis market is estimated to reach at a value of US$ 18,560.5 Mn by the end of 2022 and expected to reach at a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2%.

Advances in clinical research and molecular diagnostic technology is expected to drive the viral molecular diagnosis market

The global viral disease diagnosis market is segmented on the basis of technique, product, virus type, end use, and region

Some of the key participating players in global Viral Disease Diagnosis market are Thermo Fisher Scientific, Adaltis S.r.l, R-Biopharm AG, Siemens Healthcare Private Limited, Toronto Bioscience, Merck KGaA, Abbott Laboratories, BioMérieux SA, Cepheid, Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd, and Becton Dickinson and Company



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK